Indian Journal of Medical and Paediatric Oncology

ORIGINAL ARTICLE
Year
: 2011  |  Volume : 32  |  Issue : 1  |  Page : 38--42

Carnitine levels and cardiac functions in children with solid malignancies receiving doxorubicin therapy


Anant Khositseth1, Suwadee Jirasakpisarn1, Samart Pakakasama1, Lulin Choubtuym2, Duangrurdee Wattanasirichaigoon1 
1 Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
2 Research Center, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Correspondence Address:
Anant Khositseth
Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, 270 Rama VI, Ratchathevee, Bangkok 10400
Thailand

Aim: Previous studies demonstrated l-carnitine decreasing doxorubicin-induced cardiotoxicity. Our objectives were to study carnitine levels and cardiac functions in children treated with doxorubicin and the effect of short-term l-carnitine supplements. Materials and Methods: Serial carnitine levels and cardiac functions were obtained in children with newly diagnosed solid malignancies before doxorubicin, after cumulative doses of ≥150 mg/m 2 and ≥300 mg/m 2 , respectively. Oral l-carnitine 100 mg/kg/day for 3 days were given to the children treated with doxorubicin at cumulative doses of ≥150 mg/m 2 and ≥300 mg/m 2 . Carnitine levels and cardiac functions were also obtained in those children before and after short-term oral l-carnitine at each cumulative dose of doxorubicin. Results: Five children (3 females), median age of 9.1 years (range 1.5-13 years) with newly diagnosed solid malignancies were enrolled in the study. Free carnitine (FC) tended to decrease while acyl-carnitine (AC) increased making AC/FC ratio increased after cumulative dose of ≥150 and ≥300 mg/m 2 but the statistics was not significant. Left ventricular (LV) systolic function was not significantly changed. Interestingly, LV global function (LV myocardial performance index) was significantly increased after 150 mg/m 2 (median 0.39, 0.27-0.51) and 300 mg/m 2 (median 0.46, 0.27-0.50) when compared to baseline (median 0.28, 0.14-0.48) (P=0.05). Carnitine levels and cardiac functions were not significantly changed after oral l-carnitine supplement at cumulative dose of ≥150 mg/m 2 (n=6) and ≥300 mg/m 2 (n=9). Conclusions: Carnitine levels tended to decrease after doxorubicin treatment. LV global dysfunction was documented early after doxorubicin. However, short-term l-carnitine supplement did not improve cardiac function.


How to cite this article:
Khositseth A, Jirasakpisarn S, Pakakasama S, Choubtuym L, Wattanasirichaigoon D. Carnitine levels and cardiac functions in children with solid malignancies receiving doxorubicin therapy.Indian J Med Paediatr Oncol 2011;32:38-42


How to cite this URL:
Khositseth A, Jirasakpisarn S, Pakakasama S, Choubtuym L, Wattanasirichaigoon D. Carnitine levels and cardiac functions in children with solid malignancies receiving doxorubicin therapy. Indian J Med Paediatr Oncol [serial online] 2011 [cited 2020 Apr 3 ];32:38-42
Available from: http://www.ijmpo.org/article.asp?issn=0971-5851;year=2011;volume=32;issue=1;spage=38;epage=42;aulast=Khositseth;type=0